Niox Group Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BJVD3B28
GBP
0.58
0.01 (2.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.03 M

Shareholding (Dec 2017)

FII

0.00%

Held by 1 FIIs

DII

100.00%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 5.46%

  • The company has been able to generate a Return on Equity (avg) of 5.46% signifying low profitability per unit of shareholders funds
2

With a growth in Net Sales of 10.59%, the company declared Very Positive results in Dec 25

3

With ROE of 9.50%, it has a expensive valuation with a 3.29 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 242 Million (Small Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

21.47%

stock-summary
Debt Equity

-0.26

stock-summary
Return on Equity

9.50%

stock-summary
Price to Book

3.29

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.69%
0%
-0.69%
6 Months
-14.54%
0%
-14.54%
1 Year
-10.0%
0%
-10.0%
2 Years
-15.54%
0%
-15.54%
3 Years
-2.37%
0%
-2.37%
4 Years
82.86%
0%
82.86%
5 Years
87.44%
0%
87.44%

Niox Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
15.30%
EBIT Growth (5y)
21.23%
EBIT to Interest (avg)
-1.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.49
Tax Ratio
56.41%
Dividend Payout Ratio
91.72%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
4.78%
ROE (avg)
5.46%

Valuation key factors

Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
3.29
EV to EBIT
20.83
EV to EBITDA
15.06
EV to Capital Employed
4.11
EV to Sales
4.58
PEG Ratio
0.36
Dividend Yield
21.47%
ROCE (Latest)
19.71%
ROE (Latest)
9.50%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2017stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Niox Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 16.51% vs 13.59% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 105.88% vs -64.21% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "48.70",
          "val2": "41.80",
          "chgp": "16.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "14.80",
          "val2": "11.90",
          "chgp": "24.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.00",
          "val2": "3.40",
          "chgp": "105.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "219.70%",
          "val2": "184.20%",
          "chgp": "3.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
48.70
41.80
16.51%
Operating Profit (PBDIT) excl Other Income
14.80
11.90
24.37%
Interest
0.20
0.20
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
7.00
3.40
105.88%
Operating Profit Margin (Excl OI)
219.70%
184.20%
3.55%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 16.51% vs 13.59% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 105.88% vs -64.21% in Dec 2024

stock-summaryCompany CV
About Niox Group Plc stock-summary
stock-summary
Niox Group Plc
Pharmaceuticals & Biotechnology
Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.
Company Coordinates stock-summary
Company Details
Northbrook House, Robert Robinson Avenue , OXFORD None : OX4 4GA
stock-summary
Tel: 44 1865 405560
stock-summary
Registrar Details